Tackling EBV-Associated Lymphoma
Published: 2018-11-01 |
Author: Susan Jenks |
Source: Cancer Therapy Advisor
Donor-derived T cells that target proteins of the Epstein-Barr virus (EBV) in relapsed or refractory lymphoma can improve overall survival in the adjuvant setting, according to research from a small study that was recently published in Blood.
The experimental T cells were infused into 26 patients, who received an allogeneic bone marrow transplant for EBV-associated lymphomas. Seven patients had active disease at the time of infusion, while 19 received the T cells after transplant as adjuvant therapy for high-risk disease.
"These patients were the sickest of the sick," having exhausted other treatment options, said Catherine M. Bollard, MD, the principal investigator, who began the phase 1 clinical trial at Baylor College of Medicine in Houston, Texas, before opening a tandem trial at Children's National in Washington, District of Columbia.
Those that had the best outcome after T-cell therapy had B-cell diseases, a finding investigators attributed, in part, to B cells' antigen-presenting role in the body, Dr. Bollard said. Two-year overall survival researched 80%, which is 12% higher than the patient group as a whole.